Lilly (Eli Lilly): Tirzepatide is a drug that combines GLP-1 and GIP receptor agonists and has demonstrated significant weight loss effects. This dual agonist mechanism makes it more effective in controlling blood sugar and weight loss than single GLP-1 receptor agonists. Novo Nordisk: A market leader with key products including GLP-1 receptor agonists, such as Semaglutide (brand names Ozempic, Wegovy). These drugs primarily mimic the GLP-1 hormone to suppress appetite and promote weight loss. Roche: Currently developing CT-966 and CT-388, two innovative drugs related to weight loss and obesity treatment. GLP-1 (Glucagon-Like Peptide-1): An incretin that stimulates insulin secretion, suppresses appetite, and delays gastric emptying. These drugs are effective in lowering blood sugar and weight. GIP (Glucose-Dependent Insulinotropic Polypeptide): Another incretin similar to GLP-1, but its primary function is to stimulate insulin release. In new drugs, combining GIP and GLP-1 mechanisms shows stronger efficacy. Amylin: A hormone co-secreted with insulin that slows gastric emptying, reduces postprandial blood sugar spikes, and suppresses appetite. Amylin analogs can be used in combination with other hormones for better weight loss effects in obesity treatment. Bimagrumab: A monoclonal antibody that focuses on muscle growth and fat reduction. It promotes muscle growth while reducing fat by blocking the Activin II receptor, differing significantly from traditional weight loss drugs as it aims to reshape the body rather than just reduce weight. This drug is especially suitable for patients who want to reduce body fat while maintaining or increasing muscle mass.
